Phospholipase D (PLD) catalyzes hydrolysis of the membrane phospholipid phosphatidylcholine to produce a lipid second messenger, phosphatidic acid, and choline (1, 2). PLD has two isoforms, PLD1 and PLD2. PLD1 has low basal activity and is activated by small G proteins, classical protein kinase C (PKC) isoforms, and phosphatidylinositol 4, 5-bisphosphate (PIP2). In contrast, PLD2 has high basal activity, requires PIP2, and is activated by ARF (ADP-ribosylation factor) and PKC. PLD has been implicated in a variety of physiological cellular functions, such as intracellular protein trafficking, cytoskeletal dynamics, membrane remodeling, and cell proliferation (3). PLD activity was previously shown to increase in response to mitogenic signals and activated oncoproteins such as EGF, insulin, v-Src, and v-Ras. PLD activity and expression are up-regulated in several types of human cancers. Elevated PLD activity has been shown to contribute to cell transformation and survival. In addition, elevated PLD expression prevents cell-cycle arrest and apoptosis (4, 5). However, the roles of PLD isoforms in cell proliferation and apoptosis are not completely understood.
INTRODUCTION
Phospholipase D (PLD) catalyzes hydrolysis of the membrane phospholipid phosphatidylcholine to produce a lipid second messenger, phosphatidic acid, and choline (1, 2). PLD has two isoforms, PLD1 and PLD2. PLD1 has low basal activity and is activated by small G proteins, classical protein kinase C (PKC) isoforms, and phosphatidylinositol 4, 5-bisphosphate (PIP2). In contrast, PLD2 has high basal activity, requires PIP2, and is activated by ARF (ADP-ribosylation factor) and PKC. PLD has been implicated in a variety of physiological cellular functions, such as intracellular protein trafficking, cytoskeletal dynamics, membrane remodeling, and cell proliferation (3). PLD activity was previously shown to increase in response to mitogenic signals and activated oncoproteins such as EGF, insulin, v-Src, and v-Ras. PLD activity and expression are up-regulated in several types of human cancers. Elevated PLD activity has been shown to contribute to cell transformation and survival. In addition, elevated PLD expression prevents cell-cycle arrest and apoptosis (4, 5). However, the roles of PLD isoforms in cell proliferation and apoptosis are not completely understood.
Protein kinase CKII (CKII) is a ubiquitous serine/threonine kinase that catalyzes the phosphorylation of a large number of cytoplasmic and nuclear proteins (6-8). The holoenzyme of CKII is a heterotetramer composed of two catalytic (α and/or α') subunits and two regulatory (β) subunits. The β subunit stimulates the catalytic activity of the α or α' subunit, mediating tetramer formation and substrate recognition. Overexpression of the CKII catalytic subunit leads to tumorigenesis in mice overexpressing Myc. Analysis of yeast expressing a temperature-sensitive mutant CKII gene showed that CKII is required for cell cycle progression in both G1 and G2/M phases. In addition, recent observations that CKII phosphorylates procaspase-2 or caspase substrate confirmed that CKII prevents apoptosis (9-11). These findings suggest that CKII plays a critical role, not only in cell growth and proliferation, but also in anti-apoptosis. Thus, there must be at least one regulatory mechanism for CKII. Recently, we showed that in non-cancer NIH3T3 cells overexpressing PLD isozymes, CKII activity is down-regulated through the proteasome-dependent degradation of CKIIβ (12). In the present study, we investigated the physiological significance of the interaction between CKII and PLD2 in HCT116 human colorectal carcinoma cells. Our results indicate for the first time that the C-terminal domain of PLD2 modulates CKII by binding to CKIIβ in HCT116 cells.
RESULTS AND DISCUSSION

Interaction between PLD2 and CKIIβ in HCT116 cells
To determine whether or not CKII is associated with PLD2 in http://bmbreports.org BMB reports . All constructs were also tested against the empty expression vector pGBT9 and pGADGH to control for autonomous activation of the hybrid proteins. PX, phox domain; PH, pleckstrin homology domain; CR, conserved region. (rhodamine) were assessed by immunocytochemical staining. Cells were counterstained with DAPI to visualize the nuclei (blue). The merged panel is a pseudocolor image generated by combining the FITC (green), rhodamine (red), and DAPI (blue) channels.
HCT116 cells, PLD2 was immunoprecipitated from HCT116 cell extracts. Normal IgG immunoprecipitation was used as a control. As shown in Fig. 1A , CKIIα and CKIIβ co-precipitated with PLD2, indicating that PLD2 interacts with CKII enzyme in HCT116 cells. Next, to determine whether or not PLD2 interacts directly with the CKIIβ subunit, we attempted to form a complex between MBP-CKIIβ and PLD2. When MBP-CKIIβ was mixed with cell extract, PLD2 bound to MBP-CKIIβ (Fig.  1B) . To identify the regions of PLD2 and CKIIβ that participate in this interaction, we used a yeast two-hybrid system. PLD2 did not bind directly to CKIIα, but the C-terminal domain (amino acids 578-933) of PLD2 interacted with CKIIβ. CKIIβ interacted with PLD2 when amino acids 1-167 were present, but not when amino acids 147-215 were present (Fig. 1C) . These results suggest that the C-terminal domain of PLD2 and the N-terminal domain of CKIIβ are necessary for the interaction between PLD2 and CKIIβ.
Co-localization of CKIIβ and PLD2 in HCT116 cells
The finding that CKIIβ associated with PLD2 implies that CKIIβ and PLD2 might co-localize to the same cell region. We investigated the intracellular localization of CKIIβ relative to that of PLD2 using immunocytochemical analysis. In HCT116 cells transfected with pcDNA-HA-CKIIβ and control vector, CKIIβ expression (green) was detected in both the cytoplasm and nucleus. However, in cells co-expressing HA-CKIIβ and PLD2, the subcellular localization of CKIIβ was significantly altered; both CKIIβ and PLD2 were prominently localized to the plasma membrane region, indicating the co-localization of CKIIβ and PLD2 at discrete sites in the cells (Fig. 2) .
